In December 2010, Mesoblast formed a strategic alliance with global biopharmaceutical company, Cephalon Inc., (now wholly owned by Teva Pharmaceutical Industries Ltd.) to develop and commercialize its novel adult stem cell therapeutics for degenerative conditions of the cardiovascular and central nervous systems. These conditions include congestive heart failure and acute myocardial infarction, stroke and Parkinson’s disease, This alliance also extends to products for augmenting bone marrow transplantation in cancer patients.
Teva is funding all late stage clinical development costs worldwide for the specific products, as well as all sales and marketing costs. Mesoblast retains all manufacturing rights and will sell finished products to Teva on a transfer price basis. Teva has a 19.9% stake in Mesoblast.
Mesoblast intends to bring other products to market either on its own or together with additional strategic partners.
These products include:
- autoimmune and inflammatory diseases
- ophthalmic indications
- orthopedic cartilage and bone conditions.
Mesoblast has formed a strategic alliance with leading biologics manufacturer, Lonza, for clinical and long-term commercial production of Mesoblast’s allogeneic adult stem cell products. The alliance will provide Mesoblast with significant commercial advantages, including certainty of capacity to meet long-term global supply of its proprietary MPC products; a purpose-built manufacturing facility to be built by Lonza exclusively for Mesoblast and exclusive access to Lonza’s cell therapy facilities in Singapore. Other commercial benefits include reduced cost of goods (COGS), increased margins on sales price, and R&D support for enhanced second generation products.